[1]张新丽,靳锋,丁文君,等.补肾活血方联合缬沙坦胶囊治疗糖尿病肾病Ⅲ期30例[J].西部中医药,2017,30(10):99-102.
　ZHANG Xinli,JIN Feng,DING Wenjun,et al.Kidney-tonifying Blood-activating Prescription Combined with Valsartan Capsules in Treating 30 Cases of Diabetic Nephropathy at Stage Ⅲ[J].Western Journal of Traditional Chinese Medicine,2017,30(10):99-102.
点击复制

补肾活血方联合缬沙坦胶囊治疗糖尿病肾病Ⅲ期30例()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年10期
页码:
99-102
栏目:
出版日期:
2017-10-15

文章信息/Info

Title:
Kidney-tonifying Blood-activating Prescription Combined with Valsartan Capsules in Treating 30 Cases of Diabetic Nephropathy at Stage Ⅲ
文章编号:
1004-6852(2017)10-0099-04
作者:
张新丽，靳锋，丁文君，王文海
甘肃省中医院肾病科，甘肃 兰州 730050
Author(s):
ZHANG Xinli, JIN Feng, DING Wenjun, WANG Wenhai
Department of Nephrology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China
关键词:
糖尿病肾病; Ⅲ期; 补肾活血方; 白介素6; 肿瘤坏死因子α
Keywords:
diabetic nephropathy;  stage Ⅲ;  kidney-tonifying blood-activating prescription;  IL-6;  TNF-α
分类号:
R587.2
文献标志码:
B
摘要:
目的：观察补肾活血方联合缬沙坦胶囊治疗2型糖尿病肾病(diabetic nephropathy，DN)Ⅲ期的临床疗效。方法：将62例患者随机分为对照组32例、观察组30例，2组均服用缬沙坦胶囊，观察组加服补肾活血方，2组均连续治疗2个月。观察2组治疗前后中医证候积分，餐前血糖（FBG）、餐后2小时血糖（2hPBG）、糖化血红蛋白（HbA1c）、尿微量白蛋白排泄率、白介素6（IL-6）、肿瘤坏死因子α（TNF-α）、尿白蛋白排泄率（UAER）、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等指标的变化情况。结果：总有效率观察组为86.67%，对照组为59.37%，2组比较差异有统计学意义(P＜0.05)；中医证候总积分治疗前后2组组内比较，差异有统计学意义(P＜0.05)；治疗后组间比较，差异也有统计学意义(P＜0.05)。FBG、2hPBG及HbA1c治疗前后2组组内比较，差异有统计学意义(P＜0.05)；治疗后组间比较，差异无统计学意义(P＞0.05)。观察组IL-6、TNF-α及UAER治疗前后比较，差异有统计学意义(P＜0.05)；对照组UAER治疗前后比较，差异有统计学意义(P＜0.05)，IL-6、TNF-α治疗前后比较，差异无统计学意义(P＞0.05)。IL-6、TNF-α及UAER治疗后2组组间比较，差异有统计学意义(P＜0.05)。TC、TG、HDL-C、LDL-C治疗前后2组组内比较，差异有统计学意义(P＜0.05)；治疗后组间比较，差异有统计学意义(P＜0.05)。AST、ALT、BUN及SCr治疗前后组内及治疗后组间比较，差异均无统计学意义(P＞0.05)。结论：补肾活血方联合缬沙坦胶囊治疗Ⅲ期DN可明显改善临床症状，以减少尿蛋白的排泄，减轻炎症反应，延缓DN的进展，且安全、有效。
Abstract:
Objective: To observe clinical effects of kidney-tonifying blood-activating prescription combined with valsartan capsules in treating diabetic nephropathy (DN) at stage Ⅲ. Methods: Sixty-two patients were randomized into 32 cases of the control group and 30 cases of the observation group, both groups took valsartan capsules, the observation group took kidney-tonifying blood-activating prescription, both groups were treated for two months consecutively. TCM syndrome scales of both groups were observed before and after treating, FBG, 2hPBG, HbA1c, urinary microalbumin excretion rate (UMER), IL-6, TNF-α, urinary albumin excretion rate (UAER), TC, TG, HDL-C, LDL-C and others were detected. Results: Total effective rate of the observation group was 86.67%, higher than 59.37% of the control group, and the difference had statistical meaning (P＜0.05); the difference presented statistical meaning in the comparisons of TCM syndrome scales before and after treating within one group (P＜0.05); the difference presented statistical meaning in the comparisons of TCM syndrome scales after treating between two groups (P＜0.05). The difference had statistical meaning in the comparison of FBG, 2hPBG and HbA1c before and after treating within one group (P＜0.05); the difference had no statistical meaning in the comparisons between both groups after treating (P＞0.05). The difference had statistical meaning in the comparisons of IL-6, TNF-α and UAER before and after treating within the observation group (P＜0.05); and the difference presented statistical meaning in the comparisons of UAER before and after treating within the control group(P＜0.05); the difference had no statistical meaning in the comparison of IL-6 and TNF-α before and after treating (P＞0.05). The difference had statistical meaning in the comparisons of IL-6, TNF-α and UAER between both groups after treating (P＜0.05). The difference had statistical meaning in the comparisons of TC, TG, HDL-C and LDL-C before and after treating within one group (P＜0.05); the difference had statistical meaning in the comparisons between both groups after treating (P＜0.05). The difference had no statistical meaning in the comparisons of AST, ALT, BUN and SCr before and after treating within one group and between both groups after treating (P＞0.05). Conclusion: Kidney-tonifying blood-activating prescription combined with valsartan capsules in treating DN at stage Ⅲ could not only improve clinical symptoms obviously, but also reduce urine protein excretion, alleviate inflammatory reaction, delay DN progression, and the therapy is safe and effective.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(10):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(10):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):96.

备注/Memo

备注/Memo:
收稿日期：2017-04-12 作者简介：张新丽(1976—)，女，副主任医师。研究方向：肾脏疾病的中西医结合诊治。
更新日期/Last Update: 2017-10-15